Page: about
Many initiatives are ongoing to implement PGx knowledge and associated guidelines in clinical practise as a way to introduce personalised medicine. We believe payor platforms have a critical responsibility in PGx, to establish a uniform and full integration in the healthcare system and to ensure that solutions based on PGx will be reimbursed and optimised for larger populations.
Our solution for healthcare platforms offers a personalised treatment advice based on current guidelines for the use of genetic biomarkers, the best solution on a patient by patient basis without disclosing genetic information. This way we can help to reduce liability risk for insurance platforms within their business activity without having to access sensitive information directly.
CEO and Co-Founder.
Anne Marieke has been a fund manager in the healthcare space for over 25 years. After her university degree in Biology, she worked for Roche and 3M Pharma as a salesrep and started working in the City from 1998 onwards as healthcare portfolio manager for Threadneedle, Credit Suisse and Amundi Asset Management. Since then, she has become a coach for companies to scale up or raise money, an angel investor and board member. She started her own company Signigene to tackle implementation of pharmacogenomics at a larger scale in 2021 with her 2 co-founders. Her strategic insight and thorough understanding of new trends and their business models across all industries is her biggest strength.
COO and Co-Founder.
With over 25 years of experience in asset management in London, Mark has held senior positions at several major firms. He was the Managing Director and Head of European Fixed Income at UBS Asset Management and led the Credit team at Aviva Investors. His expertise in quantitative analysis and risk management has greatly influenced his investment process, and risk assessment is a key part of his work at SigniGene. Mark holds an MSc in Investment Analysis from Stirling University and is an Associate of The UK Society of Investment Professionals (ASIP). He is a graduate of RMA Sandhurst, where he served for five years in the Armoured Corps
Currently he focuses on building business relationships, especially in the insurance industry and Middle East, where he has developed a wide network. Recently, Mark has advised several start-ups in industries within MedTech, Genomics, Cyber Security, SME finance, and FinTech. He has helped them improve processes, sharpen their focus, and connect with investors.
CTO and Co-Founder.
I started SigniGene with my co-founders because I wanted to help people have a better life. I knew that the journey to develop a fully fledged Pharmacogenomics As a Service infrastructure from scratch would be long and painful, but the motivation to give something back to society has never vaned.
My academic background with degrees and fellowships from Torino, Kent and Reading universities has helped me through this journey, as has owning and running successful software development companies with a portfolio of customers including software manufacturers, fund management companies, asset managers and even robotics companies.
Best of all I learned a lot about genetics and myself, working with people I admire and being a customer of my very own company.
Scan this code with an authenticator app, such as Authy or Google Authenticator, preferably on a different device, then type in the access code it shows below and click OK to check it has been set up correctly. Then save your profile and then when you sign in you will be prompted for an access code, open your authenticator to get the current value and type it in.